AC
ADAR1 Capital Management, LLC
13F filer · CIK 0001940272Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$2.19BU.S. long equity reported on 13F
Positions25638 new · 69 closed
Net flow last quarter+$161MBuys minus sells
Top 10 positions weight40.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 2026256 positions | |||||
| $240M | 11.01% | 2.30% | +29.5% | Q1 2024 | |
| $118M | 5.39% | 1.49% | -3.4% | Q4 2023 | |
| $112M | 5.11% | 0.44% | -3.9% | Q4 2023 | |
| $96.4M | 4.41% | Not reported | +70.0% | Q2 2025 | |
| $89.8M | 4.11% | 1.13% | -13.0% | Q4 2023 | |
| $64M | 2.93% | 0.30% | +136.4% | Q4 2023 | |
| $47.8M | 2.19% | 2.16% | +815.6% | Q3 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $45.7M | 2.09% | 1.16% | +7.3% | Q2 2024 |
| $39M | 1.79% | 0.37% | -27.6% | Q4 2023 | |
| $31.5M | 1.44% | 2.06% | -13.7% | Q1 2025 | |
| $31M | 1.42% | 3.23% | -17.0% | Q4 2024 | |
| $28.8M | 1.32% | 9.08% | New | Q2 2026 | |
| $26.5M | 1.21% | 0.64% | -45.0% | Q1 2024 | |
| $25.2M | 1.15% | 0.32% | -16.1% | Q4 2023 | |
| $25M | 1.15% | 1.45% | -10.5% | Q2 2024 | |
| $24.9M | 1.14% | 0.27% | +4850.2% | Q4 2025 | |
| $24.4M | 1.12% | 0.10% | +545.7% | Q2 2024 | |
| $23.1M | 1.05% | 0.79% | +44.8% | Q2 2024 | |
| $22.4M | 1.02% | 0.49% | +152.1% | Q4 2023 | |
| $20.7M | 0.95% | 0.93% | +2.1% | Q4 2023 | |
| $20.1M | 0.92% | 3.24% | -17.7% | Q4 2024 | |
| $20M | 0.91% | 4.01% | +63.2% | Q4 2023 | |
| $19.7M | 0.90% | 0.53% | +17.7% | Q4 2025 | |
| $19.6M | 0.90% | 4.62% | +2518.0% | Q4 2025 | |
| $17M | 0.78% | 1.20% | +51.4% | Q3 2024 | |
| $16.7M | 0.76% | 1.30% | -7.6% | Q3 2025 | |
| $16.4M | 0.75% | 0.04% | -34.6% | Q4 2023 | |
| $15.9M | 0.73% | 0.62% | -13.1% | Q3 2024 | |
| $15.2M | 0.70% | 3.00% | -1.7% | Q4 2023 | |
| $15.1M | 0.69% | 0.20% | -35.6% | Q1 2024 | |
| $15M | 0.69% | 5.60% | +11.8% | Q4 2024 | |
| $15M | 0.68% | 0.47% | +326.1% | Q1 2024 | |
| $14.8M | 0.68% | 17.46% | +4411.1% | Q1 2024 | |
| $13.8M | 0.63% | 0.02% | +82.7% | Q1 2024 | |
| $13.6M | 0.62% | 1.87% | +65.9% | Q4 2025 | |
| $13.4M | 0.61% | 2.44% | -23.0% | Q4 2025 | |
| $13.2M | 0.60% | 0.10% | +3.7% | Q1 2024 | |
| $13.2M | 0.60% | 0.09% | +87.4% | Q4 2023 | |
| $13.1M | 0.60% | 0.69% | +178.8% | Q4 2023 | |
| $12.6M | 0.58% | 1.55% | -1.3% | Q1 2024 | |
| $12.5M | 0.57% | 1.25% | New | Q2 2026 | |
| $12M | 0.55% | 5.93% | +0.9% | Q4 2023 | |
| $11.7M | 0.54% | Not reported | +763.2% | Q1 2026 | |
| $10.7M | 0.49% | 1.43% | +37.6% | Q2 2024 | |
| $10.6M | 0.49% | Not reported | Not reported | Q1 2026 | |
| $10.4M | 0.48% | 1.84% | +179.1% | Q3 2024 | |
| $10.2M | 0.47% | 5.54% | -8.1% | Q1 2025 | |
| $10.1M | 0.46% | 0.61% | +577.3% | Q3 2025 | |
| $10.1M | 0.46% | 0.17% | -27.2% | Q2 2024 | |
| $9.41M | 0.43% | 0.02% | +3.5% | Q4 2023 | |
| Q1 2026Reported May 18, 2026287 positions | |||||
| $155M | 9.14% | 1.78% | +5.8% | Q1 2024 | |
| $105M | 6.17% | 1.55% | -5.3% | Q4 2023 | |
| $91M | 5.36% | 0.46% | -4.2% | Q4 2023 | |
| $66.5M | 3.92% | 1.31% | +8.0% | Q4 2023 | |
| $49.4M | 2.91% | Not reported | +38.9% | Q2 2025 | |
| TPTERNTerns Pharmaceuticals, Inc. | $48.2M | 2.84% | 0.79% | +68.9% | Q4 2023 |
| $41.7M | 2.45% | 0.51% | +17.1% | Q4 2023 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $41.4M | 2.44% | 1.08% | +268.3% | Q2 2024 |
| $35.9M | 2.12% | 1.18% | +3490.9% | Q1 2024 | |
| $34.5M | 2.03% | 1.41% | Not reported | Q2 2024 | |
| $26.8M | 1.58% | 0.13% | +14.4% | Q4 2023 | |
| $26.2M | 1.54% | 2.43% | -5.9% | Q1 2025 | |
| $24.6M | 1.45% | 1.70% | Not reported | Q2 2024 | |
| $21.2M | 1.25% | 0.34% | New | Q1 2026 | |
| $21M | 1.24% | 3.90% | +205.9% | Q4 2024 | |
| $20.9M | 1.23% | 1.41% | +2601.3% | Q3 2025 | |
| $20M | 1.18% | 0.34% | +485.3% | Q2 2024 | |
| $18.4M | 1.08% | 0.31% | +311.8% | Q1 2024 | |
| $17.1M | 1.00% | 0.43% | +893.6% | Q4 2023 | |
| $16M | 0.94% | 2.00% | -18.5% | Q1 2024 | |
| $15.4M | 0.90% | 2.98% | +8.5% | Q4 2023 | |
| $15.3M | 0.90% | 0.03% | +399.3% | Q1 2024 | |
| $15.1M | 0.89% | 0.18% | -17.9% | Q4 2023 | |
| $14.5M | 0.85% | 3.95% | +13.0% | Q4 2024 | |
| $14.1M | 0.83% | 1.59% | -42.1% | Q4 2023 | |
| $13.9M | 0.82% | 0.90% | +12.4% | Q4 2023 | |
| $13.6M | 0.80% | 0.64% | -33.9% | Q2 2024 | |
| $13.3M | 0.78% | 1.04% | +19.4% | Q4 2023 | |
| $13.3M | 0.78% | 0.24% | +12.2% | Q2 2024 | |
| $13.1M | 0.77% | 3.17% | +681.9% | Q4 2025 | |
| $13M | 0.77% | 0.07% | -7.7% | Q4 2023 | |
| $12.9M | 0.76% | 0.54% | +998.5% | Q4 2025 | |
| $12.6M | 0.74% | 0.21% | -28.1% | Q1 2024 | |
| $12.1M | 0.71% | 0.73% | +24.5% | Q3 2024 | |
| $12.1M | 0.71% | 1.91% | +27.5% | Q2 2025 | |
| $12.1M | 0.71% | 1.13% | -19.8% | Q4 2025 | |
| $12M | 0.71% | 0.10% | +9.0% | Q1 2024 | |
| $11.6M | 0.68% | 0.79% | +123.9% | Q3 2024 | |
| $11.1M | 0.65% | 5.00% | -18.1% | Q4 2024 | |
| $10.9M | 0.64% | 1.37% | +268.4% | Q3 2025 | |
| $10.3M | 0.61% | Not reported | New | Q1 2026 | |
| $10.1M | 0.59% | 2.72% | +6.1% | Q4 2023 | |
| $10.1M | 0.59% | 17.81% | +140.1% | Q1 2025 | |
| $9.39M | 0.55% | 0.01% | +0.9% | Q1 2024 | |
| $8.52M | 0.50% | 0.87% | Not reported | Q1 2024 | |
| $8.42M | 0.50% | 1.98% | +5.3% | Q2 2024 | |
| $8.41M | 0.50% | 2.59% | +4522.5% | Q4 2025 | |
| $8.08M | 0.48% | 0.02% | +13.7% | Q4 2023 | |
| $8M | 0.47% | 0.71% | +4.2% | Q1 2024 | |
| $7.62M | 0.45% | 0.83% | New | Q1 2026 | |
| Q4 2025Reported Feb 18, 2026244 positions | |||||
| $178M | 13.05% | 1.68% | -2.5% | Q1 2024 | |
| $91.6M | 6.73% | 1.68% | +6.1% | Q4 2023 | |
| $74.4M | 5.46% | 0.48% | +2.4% | Q4 2023 | |
| $63.1M | 4.63% | 1.22% | +10.7% | Q4 2023 | |
| ABRNAMAvidity Biosciences, Inc. | $39.4M | 2.90% | 0.36% | +918.6% | Q3 2024 |
| $37.3M | 2.74% | Not reported | Not reported | Q2 2025 | |
| $34.3M | 2.52% | 0.44% | +4.1% | Q4 2023 | |
| $32.3M | 2.37% | 2.58% | -1.6% | Q1 2025 | |
| $26M | 1.91% | 2.81% | +86.5% | Q4 2023 | |
| $22M | 1.61% | 0.11% | +43.5% | Q4 2023 | |
| TPTERNTerns Pharmaceuticals, Inc. | $21.9M | 1.61% | 0.48% | +5316.2% | Q4 2023 |
| $17.8M | 1.31% | 2.46% | +3.4% | Q1 2024 | |
| $17.6M | 1.29% | 0.97% | +491.0% | Q2 2024 | |
| RTRAPTRAPT Therapeutics, Inc. | $17.3M | 1.27% | 1.84% | +0.4% | Q2 2024 |
| $16.5M | 1.21% | 6.12% | +53.7% | Q4 2024 | |
| $16.3M | 1.20% | 0.11% | -21.9% | Q4 2023 | |
| $15.3M | 1.12% | 3.50% | +79.9% | Q4 2024 | |
| $14.6M | 1.07% | 0.24% | +48.1% | Q4 2023 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $14.4M | 1.06% | 0.32% | +24.6% | Q2 2024 |
| $14.2M | 1.04% | 1.88% | +267.0% | Q4 2023 | |
| $13.9M | 1.02% | 2.71% | -0.8% | Q4 2023 | |
| $13.8M | 1.02% | 1.91% | -9.1% | Q2 2024 | |
| $13.7M | 1.01% | 0.88% | -12.0% | Q4 2023 | |
| CTCDTXCidara Therapeutics, Inc. | $13.2M | 0.97% | 0.19% | +177.3% | Q4 2024 |
| $12.6M | 0.93% | 1.40% | New | Q4 2025 | |
| $12.5M | 0.92% | 0.59% | +89.0% | Q3 2024 | |
| $12.1M | 0.89% | 1.56% | +26.8% | Q2 2025 | |
| $11.6M | 0.85% | 0.09% | +10.0% | Q1 2024 | |
| $11.6M | 0.85% | 0.07% | +4.3% | Q4 2023 | |
| $10.8M | 0.79% | 0.81% | +2.8% | Q4 2023 | |
| $10.7M | 0.79% | 0.32% | +3.7% | Q1 2024 | |
| $9.84M | 0.72% | 0.18% | New | Q4 2025 | |
| $9.63M | 0.71% | 1.38% | -47.1% | Q3 2025 | |
| $9.3M | 0.68% | 0.01% | -23.2% | Q1 2024 | |
| $9.14M | 0.67% | 0.25% | +7.9% | Q2 2024 | |
| $8.69M | 0.64% | 9.12% | +0.9% | Q4 2023 | |
| $8.47M | 0.62% | 0.69% | -29.3% | Q1 2024 | |
| $7.44M | 0.55% | 0.36% | +589.3% | Q3 2025 | |
| $7.36M | 0.54% | 0.02% | -11.9% | Q4 2023 | |
| $7.19M | 0.53% | 2.20% | New | Q4 2025 | |
| $6.98M | 0.51% | 3.29% | +33256.7% | Q4 2023 | |
| $6.37M | 0.47% | 0.10% | New | Q4 2025 | |
| $6.22M | 0.46% | 0.01% | +95.9% | Q3 2025 | |
| $6.19M | 0.45% | 0.17% | +855.2% | Q3 2025 | |
| $6.18M | 0.45% | 2.98% | +526.9% | Q4 2024 | |
| AAAAMApollo Asset Management, Inc. | $6.17M | 0.45% | 57835.90% | Not reported | Q3 2024 |
| $6.06M | 0.45% | 2.12% | +3127.4% | Q4 2023 | |
| $5.95M | 0.44% | 5.13% | -39.1% | Q2 2024 | |
| $5.86M | 0.43% | 0.00% | Not reported | Q4 2024 | |
| $5.73M | 0.42% | 3.00% | +972.8% | Q2 2024 | |
| Q3 2025Reported Nov 14, 2025193 positions | |||||
| $115M | 10.77% | 2.13% | -56.0% | Q1 2024 | |
| $85.3M | 8.01% | 13.26% | Not reported | Q4 2023 | |
| $65.7M | 6.17% | 1.58% | +4.3% | Q4 2023 | |
| $50.6M | 4.76% | 0.49% | +72.5% | Q4 2023 | |
| $36.4M | 3.42% | Not reported | +141.1% | Q2 2025 | |
| $36.1M | 3.39% | 1.28% | +319.0% | Q4 2023 | |
| 8ETNB89bio, Inc. | $31.1M | 2.92% | 1.42% | +141.2% | Q4 2023 |
| $29.4M | 2.77% | 0.08% | +2.2% | Q4 2023 | |
| $28.5M | 2.68% | 0.43% | -10.9% | Q4 2023 | |
| $22.1M | 2.08% | 2.64% | +38.9% | Q1 2025 | |
| $14.3M | 1.35% | 2.73% | -56.5% | Q4 2023 | |
| $14.2M | 1.33% | 0.14% | +5.3% | Q4 2023 | |
| $13.2M | 1.24% | 1.51% | +2.7% | Q4 2023 | |
| RTRAPTRAPT Therapeutics, Inc. | $13.1M | 1.23% | 3.07% | -35.2% | Q2 2024 |
| $12.9M | 1.21% | 2.45% | +31.3% | Q1 2024 | |
| $11.8M | 1.11% | 0.79% | -28.1% | Q4 2023 | |
| $11.1M | 1.04% | 5.24% | -3.0% | Q4 2024 | |
| $10.6M | 1.00% | 1.95% | +28.8% | Q4 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $10.3M | 0.97% | 0.26% | +367.5% | Q2 2024 |
| $10.2M | 0.96% | 2.79% | +955.7% | Q2 2024 | |
| $10M | 0.94% | 0.32% | -52.4% | Q1 2024 | |
| $9.27M | 0.87% | 1.04% | -5.8% | Q4 2023 | |
| $8.83M | 0.83% | 0.02% | +367.1% | Q1 2024 | |
| $8.75M | 0.82% | 0.08% | -9.9% | Q1 2024 | |
| $8.58M | 0.81% | 0.58% | +465.4% | Q1 2024 | |
| $8.5M | 0.80% | 7.01% | +2.5% | Q4 2024 | |
| $8.11M | 0.76% | 3.44% | New | Q3 2025 | |
| MMTSRMetsera, Inc. | $7.98M | 0.75% | 0.15% | New | Q3 2025 |
| $7.95M | 0.75% | 9.16% | Not reported | Q4 2023 | |
| $7.92M | 0.74% | 8.42% | Not reported | Q2 2024 | |
| $7.78M | 0.73% | 0.21% | Not reported | Q1 2024 | |
| $7.67M | 0.72% | 0.16% | +117.3% | Q4 2023 | |
| $7.67M | 0.72% | 0.90% | -17.5% | Q2 2024 | |
| $7.59M | 0.71% | 0.25% | -27.1% | Q2 2024 | |
| $7.23M | 0.68% | 0.06% | +2492.4% | Q4 2023 | |
| $7.1M | 0.67% | 1.15% | -44.8% | Q1 2024 | |
| $6.74M | 0.63% | 0.33% | +66.3% | Q4 2023 | |
| $6.5M | 0.61% | 0.07% | +3.7% | Q4 2023 | |
| AAAAMApollo Asset Management, Inc. | $6.08M | 0.57% | 57835.90% | Not reported | Q3 2024 |
| $5.8M | 0.55% | 0.63% | +13.2% | Q1 2024 | |
| VPVRNAVerona Pharma plc | $5.49M | 0.52% | 0.01% | +80.8% | Q3 2024 |
| $5.48M | 0.51% | Not reported | Not reported | Q4 2024 | |
| $5.41M | 0.51% | 0.02% | -22.6% | Q4 2023 | |
| $5.01M | 0.47% | 0.07% | +9.2% | Q1 2024 | |
| $4.7M | 0.44% | 0.03% | Not reported | Q4 2023 | |
| $4.62M | 0.43% | 0.16% | +159.4% | Q4 2023 | |
| $4.1M | 0.39% | 1.25% | +9312.4% | Q2 2025 | |
| $4.1M | 0.38% | 0.37% | +355.9% | Q3 2024 | |
| $3.72M | 0.35% | 0.31% | +262.8% | Q3 2024 | |
| $3.5M | 0.33% | 0.01% | +642.1% | Q1 2024 | |
Premium opens every quarter this fund has filed